Table of Contents
Boost: Celebrity fans include actress Rebel Wilson
Pharmaceutical giant Novo Nordisk will reveal this week the growing demand for its weight-loss drugs.
The Danish company’s revenue has been boosted by the exploding popularity of its diabetes and obesity drugs, Ozempic and Wegovy.
Analysts expect it to report sales of £7.7bn for April-June on Wednesday, compared with £3.9bn in the same quarter last year.
Wegovy is an injection that tricks the body into thinking it is full. It is available on the NHS (National Health Service) but is particularly popular in the US. Its celebrity fans include actress Rebel Wilson.
Novo Nordisk is now worth £210bn.
Shares have risen 64 percent over the past year.
DIY INVESTMENT PLATFORMS
AJ Bell
AJ Bell
Easy investment and ready-to-use portfolios
Hargreaves Lansdown
Hargreaves Lansdown
Free investment ideas and fund trading
interactive investor
interactive investor
Flat rate investing from £4.99 per month
Saxo
Saxo
Get £200 back in trading commissions
Trade 212
Trade 212
Free treatment and no commissions per account
Affiliate links: If you purchase a product This is Money may earn a commission. These offers are chosen by our editorial team as we believe they are worth highlighting. This does not affect our editorial independence.
